MyD88 Deficiency (MONDO:0012839): Comprehensive Disease Characteristics Report

Summary

MyD88 deficiency is a rare autosomal recessive inborn error of immunity (primary immunodeficiency) caused by biallelic germline loss-of-function mutations in MYD88 (chromosome 3p22.2), the intracellular adaptor protein that nucleates the "Myddosome" signaling complex downstream of most Toll-like receptors (TLRs) and all interleukin-1 receptor (IL-1R) family receptors. Loss of MyD88 abolishes NF-κB– and MAPK-driven pro-inflammatory signaling through these receptors, producing a strikingly narrow clinical phenotype: patients suffer early-onset, recurrent, and often life-threatening invasive pyogenic bacterial infections, overwhelmingly dominated by Streptococcus pneumoniae, while retaining normal resistance to most viruses, fungi, parasites, and the vast majority of bacteria. The disease is clinically indistinguishable from IRAK-4 deficiency, its immediate downstream kinase partner.

A defining and clinically dangerous feature is a weak or delayed systemic inflammatory response (low or absent fever, low CRP) even during overwhelming invasive infection, which undermines early clinical detection and drives mortality. The natural history is bimodal in risk: mortality is highest in the first years of life (first invasive infection before age 2 in ~88% of patients, neonatal in ~33%), and outcomes improve markedly with age as adaptive immunity progressively compensates. More recent work has expanded the recognized phenotype beyond pyogenic bacteria to include a substantially increased risk of hypoxemic COVID-19 pneumonia (mediated by defective TLR7-dependent type I interferon production in plasmacytoid dendritic cells) and a selective defect in T-independent anti-polysaccharide IgM antibody responses linked to reduced marginal-zone-like B cells.

Management is preventive and supportive: lifelong antibiotic prophylaxis, pneumococcal (and other) vaccination, immunoglobulin replacement, and aggressive empirical antibiotics at the first suspicion of infection. There is no approved gene-specific or curative therapy in routine use. This report synthesizes 8 confirmed findings drawn from 24 reviewed papers, spanning the disease's genetics, mechanism, clinical spectrum, epidemiology, diagnostics, prognosis, treatment, and its mouse model, and maps them onto the 15-section disease-characteristics template.

Key Findings

Finding 1 — A narrow but lethal pyogenic-infection immunodeficiency

MyD88 deficiency was first defined by von Bernuth et al. (Science 2008) in nine children from unrelated kindreds carrying autosomal recessive MYD88 loss-of-function alleles. These patients experienced "life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease" yet were "otherwise healthy, with normal resistance to other microbes" (PMID: 18669862). The mechanistic conclusion drawn from this experiment of nature was that "the MyD88-dependent TLRs and IL-1Rs are therefore essential for protective immunity to a small number of pyogenic bacteria, but redundant for host defense to most natural infections." This redundancy — surprising given the central position of MyD88 in innate immunity — is the single most important conceptual takeaway of the disease and stands in sharp contrast to the broad susceptibility seen in the mouse knockout (Finding 6). The corresponding OMIM entry is #612260.

Finding 2 — Clinical cohort: pneumococcus dominates, inflammation is blunted, onset is early, early mortality is high

The largest natural-history study, Picard et al. (Medicine 2010), pooled 48 IRAK-4– and 12 MyD88-deficient patients across 37 kindreds in 15 countries and found the two disorders clinically indistinguishable (PMID: 21057262). Key quantitative features:

The blunted inflammatory response — "Systemic signs of inflammation were usually weak or delayed" — is pathognomonic and clinically treacherous: patients can be severely septic with minimal fever or CRP elevation. Crucially, outcome improves with age, indicating that adaptive immunity (antibody-mediated and other MyD88-independent mechanisms) progressively substitutes for the missing innate pathway.

Finding 3 — Mechanism: MyD88 nucleates the Myddosome

The molecular lesion sits at the apex of a defined signaling complex. Lin, Lo & Wu (Nature 2010) solved the crystal structure of the MyD88–IRAK4–IRAK2 death-domain (DD) complex, revealing a left-handed helical oligomer of 6 MyD88, 4 IRAK4, and 4 IRAK2 death domains (PMID: 20485341). Assembly is strictly hierarchical: "MyD88 recruits IRAK4 and the MyD88-IRAK4 complex recruits the IRAK4 substrates IRAK2 or the related IRAK1. Formation of these Myddosome complexes brings the kinase domains of IRAKs into proximity for phosphorylation and activation." This structural understanding explains why the loss of the single upstream adaptor is catastrophic for the whole pathway, and why MyD88 and IRAK-4 deficiencies are phenotypically identical.

Functional validation of patient variants comes from George et al. (2011), who showed that the death-domain missense variants S34Y and R98C "showed severely reduced NF-κB activation due to reduced homo-oligomerization and IRAK4 interaction" (PMID: 20966070). This directly links specific pathogenic alleles to a defect in Myddosome nucleation and downstream NF-κB output.

Finding 4 — Expanded phenotype: hypoxemic COVID-19 via impaired pDC type I IFN

García-García et al. (J Exp Med 2023) reported 22 unvaccinated MyD88- or IRAK-4-deficient patients infected with SARS-CoV-2 (17 kindreds, 8 countries); 16 were hospitalized (6 moderate, 4 severe, 6 critical, 1 death). Risk of hypoxemic pneumonia increased with age, and the odds ratio for requiring invasive mechanical ventilation versus general-population controls was a striking 74.7 (95% CI 26.8–207.8, P<0.001) (PMID: 36880831). The authors note these patients "were long thought to be selectively vulnerable to pyogenic bacteria, but also have a high risk of hypoxemic COVID-19 pneumonia," attributable to "impaired TLR7-dependent type I IFN production by pDCs, which do not sense SARS-CoV-2 correctly." This finding is mechanistically important because it demonstrates a specific viral vulnerability arising from the loss of the endosomal-TLR7 → MyD88 → type I IFN axis in plasmacytoid dendritic cells, complementing the classical bacterial phenotype.

Finding 5 — Humoral defect: impaired T-independent IgM and reduced marginal-zone-like B cells

Maglione et al. (J Immunol 2014) demonstrated a B-cell/antibody component to the disease: "patients with IRAK-4 and MyD88 deficiencies have reduced serum IgM, but not IgG antibody, recognizing T-independent bacterial antigens" and "have fewer immunoglobulin M (IgM)⁺IgD⁺CD27⁺ B cells" (PMID: 25320238). Specific IgM quantity correlated with the frequency of this marginal-zone-like B-cell subset, and patient cells showed impaired TLR7/TLR9-induced proliferation of this population. This provides a satisfying mechanistic link between the innate signaling defect and susceptibility to encapsulated (polysaccharide-coated) pyogenic bacteria such as S. pneumoniae, whose control depends heavily on rapid T-independent anti-polysaccharide IgM.

Finding 6 — The mouse model: broad TLR/IL-1 defect, but broader infection susceptibility than humans

Adachi/Akira et al. (Immunity 1998) generated Myd88⁻/⁻ mice, establishing the foundational model. These mice "have defects in T cell proliferation as well as induction of acute phase proteins and cytokines in response to IL-1" and abolished IL-18-induced IFN-γ, NK activity, and NF-κB/JNK activation, confirming that "MyD88 is a critical component in the signaling cascade that is mediated by IL-1 receptor as well as IL-18 receptor" (PMID: 9697844). Importantly, later Myd88⁻/⁻ studies revealed susceptibility to a broad range of pathogens — a notable species discordance with the narrow human phenotype. This discordance is itself a scientifically important observation: it implies redundancy mechanisms operate differently (or more robustly) in humans, and it is a key limitation for translating mouse findings.

Finding 7 — Management: prophylaxis and vigilance help, but breakthrough disease remains lethal

The therapeutic reality is captured by McKelvie et al. (2014), a case of an IRAK-4-deficient girl (clinically identical to MyD88 deficiency) "managed with antibiotic prophylaxis (sulfa/trimethoprim/PenV, then - due to neutropenia - Cefprozil), pneumococcal vaccination (PCV-7, Pneumovax23, PCV-13) and vigilance" (PMID: 24596024). She remained infection-free for six years with satisfactory (but short-lived) IgG responses to pneumococcal polysaccharide — yet died within 24 hours of an insidious S. pneumoniae serotype 6C meningitis presenting with only a low fever. The case crystallizes the central danger: "IRAK-4 deficiency causes IL-1R and TLR signaling failure, resulting in minimal clinical features despite invasive bacterial infection." Prophylaxis reduces but does not eliminate the risk of fulminant, clinically silent invasive disease.

Finding 8 — Genetic basis: biallelic germline LoF MYD88, the mechanistic opposite of somatic MYD88 L265P

The disease is caused by biallelic germline loss-of-function variants in MYD88 (HGNC:7562; NCBI Gene 4615; locus 3p22.2). MyD88 is a 296-amino-acid adaptor with an N-terminal death domain and a C-terminal TIR (Toll/IL-1R) domain. First-described alleles are private and heterogeneous point mutations and small deletions (e.g., E52del, L93P, R196C) (PMID: 18669862). Death-domain missense variants S34Y and R98C abolish signaling by impairing homo-oligomerization and IRAK4 recruitment (PMID: 20966070; "human individuals carrying rare, naturally occurring MYD88 point mutations suffer from reoccurring life-threatening infections"). Critically, these germline LoF variants are the mechanistic opposite of the recurrent somatic activating MYD88 L265P mutation that constitutively drives NF-κB in B-cell lymphomas (Waldenström macroglobulinemia, ABC-DLBCL) — a distinction essential for correct interpretation of any MYD88 variant.

The 15-Section Disease Characteristics Report

1. Disease Information

MyD88 deficiency is a rare autosomal recessive primary immunodeficiency / inborn error of immunity in which loss of the MyD88 adaptor protein cripples signaling through most TLRs and all IL-1R-family receptors, producing selective vulnerability to a small set of pyogenic bacteria (chiefly Streptococcus pneumoniae).

• Key identifiers: OMIM #612260; MONDO:0012839; the MYD88 gene is HGNC:7562 / NCBI Gene 4615 / OMIM *602170. (Orphanet, ICD-10/ICD-11, and MeSH identifiers were not independently verified in this investigation and should be confirmed against those resources; the disorder falls under the IUIS category "Defects in intrinsic and innate immunity.")
• Synonyms / alternative names: MyD88 deficiency; MYD88 deficiency; recurrent pyogenic bacterial infections due to MyD88 deficiency; myeloid differentiation primary response 88 deficiency. It is frequently grouped clinically with its phenocopy, IRAK-4 deficiency.
• Information source: Knowledge derives from aggregated disease-level resources — small international case series and cohorts (e.g., von Bernuth 2008; Picard 2010) rather than large EHR datasets, reflecting the disorder's rarity.

2. Etiology

• Disease causal factor: Purely genetic — biallelic germline loss-of-function variants in MYD88 (Finding 8). The clinical manifestations are triggered by infection (encapsulated pyogenic bacteria; and SARS-CoV-2), so the phenotype is a gene × pathogen interaction.
• Genetic risk factors: The causal variants themselves; no established common susceptibility loci or modifier genes are documented for this Mendelian disorder. Consanguinity raises the risk of homozygosity (autosomal recessive).
• Environmental risk factors: Exposure to invasive pyogenic bacteria (especially S. pneumoniae, P. aeruginosa, S. aureus) and to SARS-CoV-2. Age is a major modifier — risk of severe bacterial disease is highest in early childhood, whereas COVID-19 risk increases with age (Findings 2, 4).
• Protective factors: Maturation of adaptive immunity with age is the principal protective factor for bacterial disease (outcomes improve with age; Finding 2). Acquired pathogen-specific antibodies (vaccine- or infection-induced) can partially substitute for the missing innate pathway — analogous to the antibody-mediated rescue described in TIRAP deficiency (PMID: 28235196).
• Gene–environment interaction: The disease is a textbook example — a fixed genetic lesion produces catastrophic disease only upon encounter with a specific narrow set of pathogens, while most microbial exposures are handled normally via redundant (MyD88-independent) pathways.

3. Phenotypes

Symptom progression is episodic (discrete invasive infection episodes) superimposed on a lifelong constitutional immune defect. Quality-of-life impact derives from recurrent hospitalizations, need for lifelong prophylaxis, infection-related sequelae (e.g., post-meningitic neurological damage), and the psychological burden of unpredictable, rapidly fatal infections; disease-specific QoL instruments have not been applied in this rare disorder.

4. Genetic / Molecular Information

• Causal gene: MYD88 (HGNC:7562; NCBI Gene 4615; 3p22.2; OMIM 602170). Protein: 296-aa adaptor, N-terminal death domain + C-terminal TIR domain*.
• Pathogenic variants: Private, heterogeneous — point mutations and small deletions. Examples: E52del, L93P, R196C (von Bernuth 2008), and death-domain missense S34Y, R98C (George 2011). Variant classification: pathogenic/likely pathogenic per functional and ACMG evidence.
• Variant types: missense, small in-frame deletion, nonsense, and splice/frameshift — all converging on loss of function.
• Allele frequency: Individually very rare/private in population databases (gnomAD); biallelic genotypes are exceedingly rare.
• Origin & functional consequence: Germline, loss-of-function (impaired Myddosome assembly / NF-κB activation). This contrasts categorically with the somatic gain-of-function MYD88 L265P of B-cell lymphomas (Finding 8).
• Modifier genes / epigenetics / chromosomal abnormalities: No established disease-specific modifier genes, epigenetic marks, or large chromosomal rearrangements are documented; the disorder is monogenic and point-mutation driven.

5. Environmental Information

• Infectious agents (central): Streptococcus pneumoniae (dominant), Pseudomonas aeruginosa, Staphylococcus aureus; and SARS-CoV-2 (hypoxemic pneumonia). NCBI Taxonomy: S. pneumoniae txid1313; P. aeruginosa txid287; S. aureus txid1280; SARS-CoV-2 txid2697049.
• Environmental toxins / occupational exposures / lifestyle factors: No established role; the disease is not driven by toxins, radiation, smoking, diet, or pollution. The relevant "environmental" exposure is microbial.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic germline loss-of-function mutation in MYD88 (e.g., S34Y, R98C, E52del) leads to absent or non-functional MyD88 adaptor protein. (demonstrated — Findings 1, 8)
2. Absent functional MyD88 prevents nucleation of the Myddosome (the 6:4:4 MyD88–IRAK4–IRAK2/1 death-domain helical oligomer), because MyD88's death domain can no longer homo-oligomerize or recruit IRAK4. (demonstrated — Findings 3, 8)
3. Failure of Myddosome assembly prevents IRAK4-mediated phosphorylation/activation of IRAK1/2, which results in failure to activate TRAF6 → IKK → NF-κB and MAPK cascades. (demonstrated — Finding 3)
4. Loss of NF-κB/MAPK output abolishes downstream signaling from most TLRs (except TLR3 and partly TLR4) and all IL-1R-family receptors (IL-1R, IL-18R, IL-33R), leading to failure to produce pro-inflammatory cytokines (IL-6, TNF, IL-1β amplification) and acute-phase responses. (demonstrated — Findings 1, 6)

Branch A — Innate myeloid/epithelial defense (bacterial): 5A. Impaired TLR/IL-1R signaling in macrophages, neutrophils, dendritic and epithelial cells results in defective early recognition and clearance of pyogenic, encapsulated bacteria, and a weak/delayed systemic inflammatory response. (demonstrated — Findings 1, 2) 6A. Leads to recurrent, rapidly progressive, clinically silent invasive pyogenic bacterial disease (pneumococcal sepsis/meningitis). (demonstrated — Findings 2, 7)

Branch B — Humoral/marginal-zone defect (bacterial): 5B. Loss of TLR7/TLR9 signaling in B cells reduces the marginal-zone-like IgM⁺IgD⁺CD27⁺ B-cell pool and impairs T-independent anti-polysaccharide IgM. (demonstrated — Finding 5) 6B. Contributes to impaired control of polysaccharide-encapsulated bacteria (esp. S. pneumoniae). (inferred link to Branch A phenotype — Finding 5)

Branch C — Antiviral pDC defect (SARS-CoV-2): 5C. Loss of endosomal TLR7 → MyD88 signaling in plasmacytoid dendritic cells impairs type I interferon production upon SARS-CoV-2 sensing. (demonstrated — Finding 4) 6C. Results in increased risk of hypoxemic COVID-19 pneumonia (OR for invasive ventilation ≈ 74.7). (demonstrated — Finding 4)

1. Compensation: With age, maturation of MyD88-independent adaptive immunity (pathogen-specific antibody) progressively substitutes, leading to improving bacterial-infection outcomes over time. (demonstrated — Finding 2)

Molecular pathways: TLR/IL-1R signaling → MyD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKK → NF-κB; parallel MAPK/JNK/p38 activation; endosomal TLR7 → IRF7 → type I IFN (in pDCs). (KEGG "Toll-like receptor signaling pathway" hsa04620; Reactome "MyD88 cascade initiated on plasma membrane" R-HSA-166058.) Cellular processes: innate immune inflammation, cytokine production, phagocyte activation/killing, B-cell proliferation. Immune involvement: immunodeficiency (not autoimmunity); combined innate-signaling and T-independent humoral defect. Suggested GO terms: GO:0002755 (MyD88-dependent toll-like receptor signaling pathway), GO:0007249 (I-κB kinase/NF-κB signaling), GO:0032760 (positive regulation of TNF production), GO:0045087 (innate immune response), GO:0006954 (inflammatory response). Suggested CL terms: CL:0000235 (macrophage), CL:0000775 (neutrophil), CL:0000784 (plasmacytoid dendritic cell), CL:0000787 (memory B cell / marginal-zone-like B cell), CL:0000236 (B cell).

7. Anatomical Structures Affected

• Organ / body-system level: The immune/hematopoietic system is primary. Clinically affected organs reflect sites of invasive infection: lungs (pneumonia — UBERON:0002048), meninges/CNS (meningitis — UBERON:0002360; UBERON:0000955), bloodstream (sepsis — UBERON:0000178), skin and soft tissue (abscesses — UBERON:0002097), bone/joints (osteomyelitis/arthritis). Secondary involvement includes post-meningitic neurological sequelae.
• Tissue / cell level: Myeloid phagocytes (macrophages CL:0000235, neutrophils CL:0000775), dendritic cells including pDCs (CL:0000784), and B-lymphocyte subsets (marginal-zone-like B cells). Epithelial barriers (airway epithelium) also rely on MyD88 for defense.
• Subcellular level: Signaling occurs at the plasma membrane and endosomal membranes (TLRs) and in the cytoplasm (Myddosome assembly, NF-κB pathway). Suggested GO cellular-component terms: GO:0010008 (endosome membrane), GO:0005886 (plasma membrane), GO:0005829 (cytosol).
• Lateralization: Not applicable — a systemic immune defect; infection sites vary.

8. Temporal Development

• Onset: Typically neonatal to early childhood. First invasive infection before age 2 in 88.3%, neonatal in 32.7% (Finding 2). Onset of individual episodes is acute, often fulminant.
• Progression / course: Episodic invasive infections on a chronic, lifelong constitutional immune deficiency. Recurrence in 72% of survivors.
• Critical period: Early childhood is the window of greatest vulnerability and highest mortality; risk attenuates with age as adaptive immunity matures (a key window for intensive prophylaxis and vaccination). Notably, COVID-19 risk trends in the opposite direction, increasing with age (Finding 4).
• Remission pattern: No spontaneous remission of the underlying defect; "improvement" reflects age-dependent adaptive compensation and effective prophylaxis.

9. Inheritance and Population

• Inheritance: Autosomal recessive (biallelic germline LoF MYD88). Consanguinity increases risk. Heterozygous carriers are healthy.
• Penetrance / expressivity: High penetrance for susceptibility, but variable expressivity in infection frequency, severity, and age of first episode — partly explained by stochastic pathogen exposure and adaptive compensation.
• Epidemiology: Ultra-rare. The defining cohorts total only a few dozen patients worldwide (12 MyD88-deficient among 60 combined MyD88/IRAK-4 patients in the largest series; Finding 2). Precise prevalence/incidence figures are not established; it is best described as an "orphan" inborn error of immunity affecting far fewer than 1 in 1,000,000.
• Population / geography: Reported across many countries (15 in Picard 2010; 8 in García-García 2023) without a defined ethnic predilection; specific alleles are private/family-specific rather than founder mutations.
• Sex ratio: Autosomal (not X-linked); no strong sex bias documented.

10. Diagnostics

• Laboratory / functional immunology: The functional hallmark is impaired pro-inflammatory cytokine production (e.g., IL-6, TNF) in response to TLR and IL-1R agonists in whole blood/leukocytes/fibroblasts, with preserved responses to TLR3 and some TLR4 readouts. A characteristically low CRP and blunted acute-phase response during invasive infection is a critical (and dangerous) diagnostic clue (Findings 2, 7).
• Immunoglobulins: Reduced serum IgM to T-independent polysaccharide antigens; reduced IgM⁺IgD⁺CD27⁺ B cells on flow cytometry (Finding 5).
• Microbiology / imaging: Blood cultures, CSF studies, and imaging directed at the invasive site (chest imaging for pneumonia; MRI for meningitis).
• Genetic testing (definitive): Sanger single-gene sequencing of MYD88, targeted immunodeficiency gene panels, or whole-exome/whole-genome sequencing confirm biallelic LoF variants. Functional validation (NF-κB reporter, cytokine assays) supports variant classification. Given the phenocopy with IRAK-4 deficiency, panels should include IRAK4.
• Differential diagnosis: IRAK-4 deficiency (clinically indistinguishable — requires genetics to separate), other congenital neutropenias, complement deficiencies, asplenia/hyposplenism, antibody deficiencies (e.g., specific polysaccharide antibody deficiency), NEMO/IκBα defects, and TIRAP/IRAK-1 defects.
• Screening: No routine newborn screening exists (the TREC newborn screen for SCID does not detect this disorder). Cascade/family genetic testing is indicated once a proband variant is known.

11. Outcome / Prognosis

• Mortality: High in early childhood. In the Picard cohort, 24 deaths among 60 patients, with 10 deaths during the first invasive episode (Finding 2). Death can occur within 24 hours of an insidious presentation despite prophylaxis (Finding 7).
• Age-dependent improvement: Outcome improves with age as adaptive immunity compensates — the dominant prognostic factor.
• Morbidity: Recurrent invasive infections (72% of survivors), potential permanent sequelae (post-meningitic neurological deficits, hearing loss), and the burden of lifelong prophylaxis.
• Prognostic factors: Age (younger = worse for bacterial disease), timeliness of empirical antibiotic treatment, adherence to prophylaxis/vaccination, and — for COVID-19 — older age (worse). No validated molecular prognostic biomarker exists; the blunted inflammatory response is itself an adverse feature because it delays recognition.

12. Treatment

There is no approved gene-corrective or curative standard-of-care; management is preventive and supportive (Findings 2, 7):

• Pharmacogenomics / targeted / gene / cell / RNA therapy: No routine gene-specific, targeted, cell-, or RNA-based therapy is established. Hematopoietic stem cell transplantation is not standard given age-dependent improvement, though it is conceptually curative for the hematopoietic defect. Gene therapy is discussed as a future prospect in the inborn-errors-of-immunity literature (PMID: 41369391) but is not clinically available for this disorder.
• Combination / personalized strategy: The mainstay is a combination of prophylaxis + vaccination + immunoglobulin + rapid empirical treatment, individualized to infection history.

13. Prevention

• Primary prevention: Not possible for the genetic lesion; relevant primary prevention is against infection — vaccination and antibiotic prophylaxis (Finding 7).
• Secondary prevention: Early detection of infection despite blunted signs — heightened vigilance, family education, low threshold for cultures and empirical antibiotics.
• Tertiary prevention: Prevention of infection complications and recurrences through sustained prophylaxis and immunoglobulin replacement.
• Genetic counseling / reproductive options: For autosomal recessive disease with a known variant — carrier testing, cascade screening, prenatal testing, and preimplantation genetic diagnosis are available. Counseling on 25% recurrence risk for future pregnancies of carrier couples; consanguinity counseling.
• Immunization is central: Unlike many primary immunodeficiencies where live vaccines are contraindicated, polysaccharide/conjugate and inactivated vaccines are actively recommended here.

14. Other Species / Natural Disease

• Taxonomy / orthology: MYD88 is highly conserved. Mouse Myd88 (NCBI Gene 17874; Mus musculus txid10090) is the principal experimental ortholog; orthologs exist across vertebrates.
• Natural disease in other species: No well-characterized naturally occurring MyD88-deficiency disease in companion animals or wildlife is documented in this investigation; the animal knowledge base is essentially the engineered mouse knockout (Finding 6), not spontaneous veterinary disease.
• Comparative pathology / evolutionary conservation: The MyD88 → IRAK → NF-κB module is evolutionarily ancient and broadly conserved. However, there is a notable human–mouse phenotypic discordance: Myd88⁻/⁻ mice show broad infection susceptibility, whereas humans show a narrow pyogenic-bacterial phenotype (Finding 6), indicating species differences in pathway redundancy.
• Zoonotic potential: Not applicable (a host genetic disorder, not a transmissible disease).

15. Model Organisms

• Primary model: The Myd88⁻/⁻ knockout mouse (Adachi/Akira, Immunity 1998; Finding 6) — a mammalian, whole-body gene-targeted knockout. It faithfully reproduces the signaling defect: abolished IL-1– and IL-18–mediated responses, impaired acute-phase/cytokine induction, defective NF-κB/JNK activation, and impaired Th1 responses.
• Phenotype recapitulation: Excellent for the molecular/signaling phenotype and for demonstrating MyD88's role as an essential adaptor. Limitation: the mouse displays broader pathogen susceptibility than the narrow human phenotype, so it over-predicts clinical vulnerability and cannot fully model the human redundancy that spares patients from most infections.
• Other models: Patient-derived fibroblasts and leukocytes serve as in vitro systems (TLR/IL-1R agonist stimulation, NF-κB reporter assays) for functional variant validation (e.g., S34Y/R98C studies; Findings 3, 8). Conditional/tissue-specific Myd88 mice (e.g., epithelial-specific) have illuminated organ-level roles in related contexts.
• Resources: Mouse Genome Informatics (MGI), IMPC, IMSR for Myd88 alleles.

Mechanistic Model / Interpretation

   GERMLINE BIALLELIC LoF MYD88 (3p22.2; e.g., S34Y, R98C, E52del)
                     │  (Findings 1, 8)
                     ▼
   No functional MyD88 adaptor  ──►  MYDDOSOME CANNOT FORM
   (death domain can't oligomerize / recruit IRAK4)   (Finding 3)
                     │
                     ▼
   No IRAK4→IRAK1/2 activation ─► no TRAF6/TAK1/IKK ─► NO NF-κB / MAPK
                     │  (Finding 3)
        ┌────────────┼───────────────────────────┐
        ▼            ▼                             ▼
 [Branch A]     [Branch B]                    [Branch C]
 Myeloid/epith. B-cell TLR7/9 defect          pDC TLR7 defect
 TLR/IL-1R       ↓ MZ-like IgM+IgD+CD27+       ↓ type I IFN
 defense fails   ↓ T-indep. anti-poly IgM      (Finding 4)
 + weak          (Finding 5)                        │
 inflammation                                       ▼
 (Findings 1,2)       └──────────┐          Hypoxemic COVID-19
        │                        ▼          (OR ~74.7 for IMV)
        ▼            Poor control of encapsulated
 Recurrent invasive  pyogenic bacteria (S. pneumoniae)
 pyogenic bacterial  ◄──────────┘
 disease; silent
 presentation → death
 (Findings 2, 7)
        │
        ▼
 AGE-DEPENDENT ADAPTIVE COMPENSATION → improving prognosis (Finding 2)

The unifying interpretation is that MyD88 sits at a single obligatory node for a large family of innate receptors, yet in humans this node proves redundant for defense against most microbes — the immune system's layered architecture (complement, MyD88-independent TLR3/TRIF, adaptive antibody) covers the great majority of threats. The disease therefore reveals which pathogens are uniquely dependent on MyD88-driven innate inflammation and rapid T-independent IgM: encapsulated pyogenic bacteria (above all S. pneumoniae), plus — via the specialized pDC TLR7/type I IFN branch — SARS-CoV-2. The blunted inflammatory response is not incidental but a direct consequence of the lesion, and it is the proximate cause of much of the mortality because it removes the clinical "alarm." Finally, the age-dependent improvement provides both prognostic guidance and a therapeutic rationale: passive antibody (immunoglobulin) and active vaccination substitute for the missing innate arm.

Evidence Base

All quoted snippets in the Key Findings section are verbatim from the cited abstracts. Evidence types span human clinical (von Bernuth, Picard, García-García, Maglione, McKelvie), structural/in vitro (Lin/Wu, George), and model organism (Adachi/Akira).

Limitations and Knowledge Gaps

• Extreme rarity → small numbers: The pivotal cohorts total only a few dozen patients (with MyD88-deficient individuals a minority of pooled MyD88/IRAK-4 series). Prevalence, incidence, precise mortality rates, and sex/geographic distributions are therefore imprecise.
• Phenocopy conflation: Much clinical data pool MyD88 and IRAK-4 deficiency because they are indistinguishable; some MyD88-specific quantitative estimates are inferred from the combined cohort.
• Identifiers partially unverified: Orphanet, ICD-10/ICD-11, and MeSH identifiers were not independently confirmed in this investigation and should be validated against those primary resources before database ingestion.
• Human–mouse discordance: The Myd88⁻/⁻ mouse over-predicts susceptibility, limiting its use for modeling the human redundancy — the mechanistic basis of the human's narrow phenotype remains incompletely explained.
• Allele frequency & penetrance quantitation: Because variants are private, population allele frequencies and formal penetrance/expressivity metrics are not tabulated here.
• Therapeutic evidence is observational: Management recommendations rest on case series and expert practice, not randomized trials; the true efficacy of each preventive component is not quantified.
• Epigenetics, modifiers, QoL: No disease-specific epigenetic data, validated genetic modifiers, or formal quality-of-life measurements were identified.

Proposed Follow-up Experiments / Actions

1. Verify and complete cross-references: Confirm Orphanet, ICD-10/ICD-11, MeSH, and MONDO mappings directly from those resources to finalize Section 1 identifiers.
2. Compile a curated MYD88 variant table from ClinVar/HGMD with ACMG classifications, variant type, domain location (death vs TIR), functional data, and gnomAD frequencies — to enrich Section 4.
3. Quantitative natural-history synthesis: Aggregate published MyD88-specific cases (separating them from IRAK-4) to derive age-stratified infection incidence, causative organisms, and survival curves.
4. Mechanistic dissection of human redundancy: Comparative functional immunology (e.g., single-cell profiling of patient vs control innate cells under defined stimuli) to explain why humans tolerate MyD88 loss for most pathogens while mice do not.
5. Prospective assessment of COVID-19 and other viral risks in genotyped patients, and evaluation of type I IFN or vaccination strategies for the pDC/TLR7 branch (Finding 4).
6. Evaluate immunoglobulin replacement and prophylaxis efficacy systematically (registry-based), including optimal antibiotic choice and vaccination schedules, given the demonstrated risk of fatal breakthrough disease.
7. Biomarker development for the "silent infection" problem: Identify early molecular indicators of invasive infection that do not depend on the MyD88-driven acute-phase response (which is blunted), to enable earlier intervention.

Report compiled from 8 confirmed findings and 24 reviewed papers across a 5-iteration autonomous investigation. Evidence classes: human clinical, structural/in vitro, and model organism. All direct quotations are verbatim from the cited PubMed abstracts.